CytoDyn Announces Progress With DNA Pre-Vaccines For Influenza

NEW YORK--(BUSINESS WIRE)--CytoDyn, Inc. (OTCBB:CYDY) announced today that optimization of the Company’s DNA-based pre-vaccines for influenza (the flu) will be reported in an upcoming issue of the Journal of Virology on line (www.jvi.asm.org). The encouraging results of the optimization technique (known as “codone optimization”) are described in a paper by S. Xang, J. Taffe, C. Parker, A. Solórzano, Hiong Cao, Adolfo García-Sastre and Shan Lu, from The University of Massachusetts Medical School, Worcester, MA, and the Mount Sinai School of Medicine, New York, NY.

Back to news